Zafirlukast
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. It is available as a tablet.
Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
Zafirlukast is marketed by AstraZeneca with the brand names Accolate, Accoleit, and Vanticon. It was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Italy, Spain, Canada, Brazil, China and Turkey.
Clinics & treatments
Medic8® Guides
- Cosmetic Surgery
- Cosmetic Dentistry
- Weight Loss Surgery
- Laser Eye Surgery
- Laser Hair Removal
- Health Insurance
- Life Insurance
- Family Health
- Travel Health
- Medical Tourism
Health centres
- Allergies
- Alternative Health
- Arthritis
- Asthma
- Blood Disorders
- Bones & Joints
- Bowel & Abdominal Problems
- Cancer
- Chest Problems
- Child Health
- Circulation Problems
- Diabetes
- Diet & Nutrition
- Drug Addiction
- Ear, Nose, & Throat Problems
- Elderly Health
- Eye Problems
- Heart Problems
- High Blood Pressure
- Hormone & Endocrine Problems
- Infections
- Infertility
- Liver Problems
- Medications
- Men's Health
- Mental Health
- Nervous System
- Personal & Social Issues
- Pregnancy & Birth
- Preventive Health
- Radiology
- Sexual Health
- Skin Problems
- Sports Medicine
- Surgery
- Travel Health
- Urinary & Kidney Problems
- Vaccination
- Women's Health
